27,105
Total Claims
$2.4M
Drug Cost
1,528
Beneficiaries
$1,555
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+2%
Cost per patient vs peers
$1,555 vs $1,524 avg
-3%
Brand preference vs peers
13.2% vs 13.7% avg
Brand vs Generic
87% generic
Brand: 3,582 claims · $2.1M
Generic: 23,467 claims · $324K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 611 | $402K |
| Apixaban | 517 | $338K |
| Rivaroxaban | 439 | $318K |
| Dapagliflozin Propanediol | 184 | $117K |
| Sitagliptin Phosphate | 122 | $75K |
| Linagliptin | 123 | $75K |
| Sacubitril/Valsartan | 90 | $65K |
| Evolocumab | 111 | $64K |
| Sodium Zirconium Cyclosilicate | 80 | $64K |
| Empagliflozin/Linagliptin | 87 | $54K |
| Empaglifloz/Linaglip/Metformin | 72 | $46K |
| Sitagliptin Phos/Metformin Hcl | 60 | $34K |
| Dulaglutide | 32 | $30K |
| Atorvastatin Calcium | 2,988 | $30K |
| Insulin Glargine,hum.Rec.Anlog | 63 | $24K |
Prescribing Profile
Patient Profile
73
Avg Age
62%
Female
2.01
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data